| Code | Description | Claims | Beneficiaries | Total Paid |
| 71046 |
Radiologic examination, chest; 2 views |
994 |
846 |
$160K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
1,664 |
1,432 |
$146K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
355 |
315 |
$105K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
629 |
547 |
$99K |
| 80053 |
Comprehensive metabolic panel |
7,492 |
6,338 |
$57K |
| 70450 |
Computed tomography, head or brain; without contrast material |
64 |
58 |
$43K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
3,378 |
1,434 |
$43K |
| 71045 |
Radiologic examination, chest; single view |
259 |
224 |
$33K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
5,650 |
4,712 |
$32K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
410 |
368 |
$31K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
653 |
540 |
$30K |
| 36415 |
Collection of venous blood by venipuncture |
12,506 |
10,147 |
$27K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
874 |
565 |
$27K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
587 |
530 |
$14K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
44 |
37 |
$8K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
1,148 |
1,080 |
$8K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
526 |
461 |
$7K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
75 |
71 |
$7K |
| J3490 |
Unclassified drugs |
459 |
232 |
$4K |
| 80061 |
Lipid panel |
345 |
325 |
$4K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
205 |
143 |
$3K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
106 |
54 |
$3K |
| 84443 |
Thyroid stimulating hormone (TSH) |
194 |
178 |
$2K |
| 84484 |
|
246 |
198 |
$2K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
120 |
87 |
$2K |
| 85027 |
|
302 |
246 |
$1K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
46 |
37 |
$1K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
46 |
37 |
$1K |
| 81001 |
|
577 |
489 |
$1K |
| 0001A |
|
48 |
46 |
$1K |
| 85007 |
|
526 |
432 |
$1K |
| 80050 |
General health panel |
31 |
28 |
$1K |
| 83880 |
|
35 |
29 |
$932.73 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
101 |
79 |
$499.38 |
| 0002A |
|
19 |
17 |
$482.04 |
| J8499 |
Prescription drug, oral, non chemotherapeutic, nos |
68 |
36 |
$481.65 |
| 87280 |
|
30 |
29 |
$402.60 |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
76 |
66 |
$288.81 |
| 82550 |
|
31 |
25 |
$136.93 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
17 |
17 |
$48.62 |
| 91300 |
|
91 |
76 |
$16.00 |
| A9150 |
Non-prescription drugs |
12 |
12 |
$7.03 |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
423 |
351 |
$0.00 |
| T1015 |
Clinic visit/encounter, all-inclusive |
199 |
176 |
$0.00 |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
16 |
16 |
$0.00 |